Ignite Creation Date:
2024-05-06 @ 8:27 PM
Last Modification Date:
2024-10-26 @ 3:27 PM
Study NCT ID:
NCT06383533
Status:
RECRUITING
Last Update Posted:
2024-04-26
First Post:
2024-04-22
Brief Title:
Disitamab Vedotin Plus Cadonilimab in Patients With HER2 Mutant Advanced or Metastatic Bile Duct Adenocarcinoma
Sponsor:
Zhejiang Cancer Hospital
Organization:
Zhejiang Cancer Hospital
Conditions & Keywords Data
Conditions:
| Name |
|---|
| Bile Duct Adenocarcinoma Non-Resectable |
| HER2 Gene Mutation |
Keywords: